Navigation path

461 - Cost-containment policies in public pharmaceutical spending in the EU

Giuseppe Carone, Christoph Schwierz, Ana Xavier

Cost-containment policies in public pharmaceutical spending in the EUpdf(931 kB) Choose translations of the previous link 

Summary for non-specialistspdf(33 kB)


This paper presents and evaluates pharmaceutical policies in the EU aimed at the rational use of medicines and at keeping pharmaceutical spending under control. Policy makers are growing more aware that by regulating pharmaceutical markets correctly, considerable savings can be achieved without compromising the quality of care. Specifically, the paper makes the case that, by following numerous best-practices in pharmaceutical sector regulations, the value for money of pharmaceutical consumption could be substantially increased. Appropriate regulations can be relevant for pricing, reimbursement, market entry and expenditure control, as well as specific policies targeted at the distribution chain, physicians and patients. Drawing on various initiatives at the EU level related to the pharmaceutical sector, the paper also explores policy options for the EU.
(European Economy. Economic Papers. 461. September 2012. Brussels. PDF. 62pp. Tab. Graph. Ann. Free.)

KC-AI-12-461-EN-N (online)
ISBN ISBN 978-92-79-22982-4 (online)
doi:10.2765/27111 (online)

JEL classification: I11, I18

Additional tools

  • Print version 
  • Decrease text 
  • Increase text